Share on StockTwits

Stock analysts at Gabelli assumed coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a report issued on Friday. The firm set a “buy” rating on the stock.

In other Tetraphase Pharmaceuticals news, Insider Guy Macdonald unloaded 15,000 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $12.28, for a total transaction of $184,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 12.99 on Friday. Tetraphase Pharmaceuticals has a 1-year low of $7.02 and a 1-year high of $17.74. The stock has a 50-day moving average of $10.31 and a 200-day moving average of $12.24. The company’s market cap is $335.6 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.08. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.97 million. Analysts expect that Tetraphase Pharmaceuticals will post $-2.07 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $21.00 price target on the stock. Separately, analysts at WBB Securities upgraded shares of Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $16.00 price target on the stock, up previously from $13.50. Finally, analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Thursday, April 3rd. They set a “buy” rating and a $23.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, Tetraphase Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $18.75.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.